literature

HIV mutation literature information.

Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.

PMID: 35274144 2022 The Journal of antimicrobial chemotherapy

Abstract: PBMC DNA deep sequencing performed some months later revealed mutations M184I (14.29%) and M230I (6.25%) in the reverse transcriptase and G163R (9.77%) and S230N (98.8%) in the integrase.

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Result: Three participants had additional treatment-emergent resistance-associated reverse transcriptase substitutions of T215F/L, T215F/I/S/T and M230I/M, or M184V (n = 1 each) at PDVF.

Table: M230I/M

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

PMID: 34871089 2022 Antimicrobial agents and chemotherapy

Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNRTI RAMs at screening were excluded: A98G, L100I, K101E, K101P, K101Q, K103H, K103N, K103S, K103T, V106A, V106M, V108I, E138A, E138G,

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.

PMID: 35001501 2022 Journal of the International AIDS Society

Method: We excluded individuals with prior evidence of NNRTI-associated resistance mutations based on the IAS-USA HIV drug-resistance mutations list (2019) (V90I, A98G, L100I, K101E/H/P/Q/R/N, K103N/S, V106A/M/I, V108I, E138K/A/G/Q/R, V179D/F/L/T, Y181C/I/V, Y188L/C/H, G190A/S/E,H221Y, P225H, F227L/C/R,

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: M230I/L

Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.

PMID: 33635848 2021 AIDS (London, England)

Abstract: Certain Apolipoprotein B Editing Complex 3-related DRMs including reverse transcriptase gene mutations M184I, E138K, M230I, G190E and protease gene mutations M46I, D30N were enriched in hypermutated sequences but not in intact sequences or plasma sequences.

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.

PMID: 34064774 2021 Viruses

Result: E138R and M230I are not present in Table 4 because they occurred in fewer than 0.1% of NNRTI-experienced persons.

Result: M230I also had a low treated/naive ratio of 4.

Result: A similar phenomenon may also explain the relatively low treated/naive prevalence ratios for E138K and M230I.

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.

PMID: 34762770 2021 Journal of the International AIDS Society

Table: M230I/L

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

PMID: 31976534 2020 The Journal of antimicrobial chemotherapy

Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V, 0.5% versus 1.8%; M230I/L, 2.8% versus 0%; L234I, 0.1% versus 0.5%; K103N + Y181C, 3.9% versus 3.9%; K103N + P225H, 2.9% versus 4.7%; and K103N + L100I, 1.7% versus 3.9%, with a significantly higher proportion of these mutations in the

The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.

PMID: 32030406 2020 The Journal of antimicrobial chemotherapy

Abstract: METHODS: We used the WHO 2009 list to investigate the prevalence of NNRTI, NRTI and PI TDR, in treatment-naive HIV-1-infected patients, adding mutations E138A/G/K/Q/R, V106I, V108I, V179L, G190Q, H221Y, F227C/L/V, M230IDR, L234I, P236L and Y318F in RT.

Browser Board

Co-occurred Entities

Filtrator